Venous and arterial thromboembolism with immunotherapy compared to platinum-based therapy

Thromb Res. 2022 Sep:217:48-51. doi: 10.1016/j.thromres.2022.07.006. Epub 2022 Jul 14.

Authors

Satish Maharaj¹, Simone Chang², Goetz Kloecker³, Jason Chesney³, Rebecca Redman³, Adam Rojan⁴

Affiliations

¹ University of Louisville, KY, USA; Texas Tech University Health Sciences Center, Division of Hematology/Oncology, 4800 Alberta-MSC41007, El Paso, Texas 79905, USA. Electronic address: satmahar@ttuhsc.edu.
² University of Louisville, KY, USA; Texas Tech University Health Sciences Center, Division of Hematology/Oncology, 4800 Alberta-MSC41007, El Paso, Texas 79905, USA.
³ University of Louisville, KY, USA.
⁴ University of Cincinnati, OH, USA.

PMID: 35853370
DOI: 10.1016/j.thromres.2022.07.006

No abstract available

Keywords: Chemotherapy; Immunotherapy; Myocardial infarction; Stroke; Venous thrombosis.

Publication types

Letter

MeSH terms

Humans
Immunotherapy
Platinum / therapeutic use
Risk Factors
Stroke*
Venous Thromboembolism* / drug therapy

Substances

Platinum